Spectrum Pharmaceuticals (SPPI) jumps on drug trials

Spectrum Pharmaceuticals (NASDAQ: SPPI) shares gained 3.3% to $7.13 after the company reported that its pivotal trial of Captisol-enabled Melphalan met its primary endpoint. Share volume topped one million, compared to an all-day average of 859,000